ACUTAAS CHEMICALS LIMITED
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 23.4%
Concerns1
- Low return on equity of 6.5%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 9 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ990.00 Cr | β | βΉ160.00 Cr | β | β | 12.2% | 43.9% | 263.6% |
| Mar 2024 | βΉ688.00 Cr | β | βΉ44.00 Cr | β | β | 6.5% | 11.5% | -47.0% |
| Mar 2023 | βΉ617.00 Cr | β | βΉ83.00 Cr | β | β | 14.2% | 18.7% | 15.3% |
| Mar 2022 | βΉ520.00 Cr | β | βΉ72.00 Cr | β | β | 13.9% | 52.5% | 33.3% |
| Mar 2021 | βΉ341.00 Cr | β | βΉ54.00 Cr | β | β | 32.9% | 42.1% | 100.0% |
| Mar 2020 | βΉ240.00 Cr | β | βΉ27.00 Cr | β | β | 25.2% | 1.7% | 8.0% |
| Mar 2019 | βΉ236.00 Cr | β | βΉ25.00 Cr | β | β | 30.9% | 25.5% | 38.9% |
| Mar 2018 | βΉ188.00 Cr | β | βΉ18.00 Cr | β | β | 31.0% | 17.5% | 50.0% |
| Mar 2017 | βΉ160.00 Cr | β | βΉ12.00 Cr | β | β | 30.0% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,086 |
| Total Expenses | 788 |
| EBIT / Operating Profit | 298 |
| OPM % | 27% |
| Other Income | 33 |
| Finance Costs | 2 |
| Depreciation & Amortisation | 27 |
| Profit Before Tax | 302 |
| Tax % | - |
| Net Profit / PAT | 226 |
| EPS (βΉ) | 27.55 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| ACUTAAS CHEMICALS LIMITEDthis co. | βΉ13.81 K Cr | βΉ990.00 Cr | 61.20 | 9.73 | 154.50 | 43.9% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |